Johnson & Johnson has announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This announcement includes an investment of $2 billion in a 500,000-square-foot biologics manufacturing facility in Wilson, North Carolina. Earlier this month (March 2025), the company broke ground on the new facility.  

The company estimates that the North Carolina facility could create approximately 5,000 construction jobs during the development of the site and that the investment will create an estimated economic impact of $3 billion statewide during the first 10 years of site operation.  

In addition to the facility in Wilson, North Carolina, the company’s increased investment in the US over the next four years includes: 

• Three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses. 

• Significant investments in R&D infrastructure for developing therapeutics in areas such as oncology, neuroscience, immunology, and cardiovascular disease as well as investments in robotic surgery. 

• Increased technology investments in drug-discovery and development activities,  workforce training, and business operations. 

• With its increased investment over the next four years, the company’s US economic impact will build upon its already estimated more than $100 billion per year. 

Source: Johnson & Johnson ($55-Bn investment plan) and Johnson & Johnson (North Carolina biomanufacturing facility)